NASDAQ:ACRV · NASDAQ Global Market
+$0.05 today
Vol 0.26M · Avg 0.60M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ACRV · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$77.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.00, tying the income statement back to per-share earnings.
Revenue
—
Operating Income
—
Net Income
—
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.4M +34.8% | $1.0M +87.7% | $536.0K | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.4M -34.8% | -$1.0M -87.7% | -$536.0K | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $60.0M -6.3% | $64.0M +40.7% | $45.5M +89.9% | $23.9M +74.6% | $13.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $24.1M -4.3% | $25.2M +18.8% | $21.2M +143.6% | $8.7M +253.1% | $2.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $82.8M -6.2% | $88.2M +32.2% | $66.7M +104.2% | $32.7M +101.8% | $16.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M +34.8% | $1.0M +87.7% | $536.0K +47.3% | $364.0K +883.8% | $37.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$76.5M +3.8% | -$79.5M -32.9% | -$59.9M -94.3% | -$30.8M -90.1% | -$16.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$84.1M +5.7% | -$89.2M -32.7% | -$67.2M -105.9% | -$32.7M -101.8% | -$16.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.5M -29.6% | $9.2M +30.8% | $7.0M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.2M -28.2% | $8.6M +26.2% | $6.8M +359.7% | $1.5M +2625.4% | -$59.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$77.9M +3.3% | -$80.6M -33.4% | -$60.4M -93.8% | -$31.2M -91.9% | -$16.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$77.9M +3.3% | -$80.6M -33.4% | -$60.4M -93.8% | -$31.2M -91.9% | -$16.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +3.8% | -$2 +23.4% | -$3 -93.0% | -$1 -12.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +3.8% | -$2 +23.4% | -$3 -93.0% | -$1 -12.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $38.5M +0.6% | $38.3M +73.5% | $22.1M +0.7% | $21.9M +69.8% | $12.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $38.5M +0.6% | $38.3M +73.5% | $22.1M +0.7% | $21.9M +69.8% | $12.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$496.47M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$172.36M
Immunic, Inc.
NASDAQ:IMUX
$148.72M
Vaxart, Inc.
NASDAQ:VXRT
$125.60M
Biomea Fusion, Inc.
NASDAQ:BMEA
$73.18M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$64.53M
Cibus, Inc.
NASDAQ:CBUS
$62.32M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$56.25M
aTyr Pharma, Inc.
NASDAQ:ATYR
$52.66M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ACRV generate?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported $0.00 of revenue in fiscal 2025.
Is ACRV profitable?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported -$77.91M of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.